|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-1-26
|
|
pubmed:abstractText |
To evaluate the impact of adjuvant cisplatin-vinorelbine in completely resected non-small cell lung cancer and identify patients likely to benefit from this regimen in the Lung Adjuvant Cisplatin Evaluation (LACE) database. The overall LACE meta-analysis showed survival benefit with cisplatin-based adjuvant chemotherapy (5-year survival benefit of 5.4%, hazard ratio [HR] 0.89, p = 0.004). Subgroup analysis for the cisplatin-vinorelbine regimen was prespecified in the LACE statistical analysis plan. Patients randomized to cisplatin-vinorelbine or observation were the largest subgroup (41%) and the most homogeneous in terms of drug doses and eligibility.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:AubertDelphineD,
pubmed-author:DingKeyueK,
pubmed-author:DouillardJean-YvesJY,
pubmed-author:LACE Collaborative Group,
pubmed-author:Le ChevalierThierryT,
pubmed-author:PignonJean PierreJP,
pubmed-author:RosellRafaelR,
pubmed-author:SeymourLesleyL,
pubmed-author:ShepherdFrances AFA,
pubmed-author:SpiroStephenS,
pubmed-author:StephensRichardR,
pubmed-author:TribodetHélèneH,
pubmed-author:VeillardAnne-SophieAS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
220-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20027124-Antineoplastic Agents,
pubmed-meshheading:20027124-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20027124-Chemotherapy, Adjuvant,
pubmed-meshheading:20027124-Chi-Square Distribution,
pubmed-meshheading:20027124-Cisplatin,
pubmed-meshheading:20027124-Female,
pubmed-meshheading:20027124-Humans,
pubmed-meshheading:20027124-Lung Neoplasms,
pubmed-meshheading:20027124-Male,
pubmed-meshheading:20027124-Meta-Analysis as Topic,
pubmed-meshheading:20027124-Neoplasm Staging,
pubmed-meshheading:20027124-Proportional Hazards Models,
pubmed-meshheading:20027124-Randomized Controlled Trials as Topic,
pubmed-meshheading:20027124-Survival Rate,
pubmed-meshheading:20027124-Treatment Outcome,
pubmed-meshheading:20027124-Vinblastine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
|
|
pubmed:affiliation |
Department of Medical Oncology, Centre R Gauducheau, St-Herblain, France. jy-douillard@nantes.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
